Treatment patterns and survival in high-grade osteosarcoma: multicenter retro study
Official title: A Multicenter Medical-Record-Based Retrospective Study of Treatment Patterns and Survival Outcomes in Patients With High-Grade Osteosarcoma
Run by MedPacto, Inc. · NCT07878364 · Data updated 2026-11-12
This study tests how patients with high-grade osteosarcoma have fared after first-line treatment across four Korean centers.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 12 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | MedPacto, Inc. Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 4 sites (Goyang-si and 3 other locations) |
| Status | Recruiting |
| Started | July 13, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | October 16, 2026 |
| Trial ID | NCT07878364 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 12 or older with pathologically diagnosed high-grade osteosarcoma who completed or ended first-line treatment at one of the participating sites by mid-2021 and have sufficient follow-up or event data.
✕Probably not a fit
Patients without adequate follow-up data or those whose diagnosis is not high-grade osteosarcoma may not benefit from the findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter, retrospective observational study using medical records to describe treatment patterns and survival outcomes in about 400 patients with high-grade osteosarcoma. It aims to estimate the 12-month event-free survival from diagnosis and to compare survival after achieving complete remission/no evidence of disease in clinically high-risk patients. Data are collected from electronic records, de-identified, and validated by independent reviewers, with standard survival analyses planned. The research provides historical reference data to inform future maintenance-therapy trials. Interventions are not being tested in this study.
Why it matters
Potential benefit: If successful, the findings could help establish historical benchmarks for survival and support design of future maintenance-therapy trials.
How similar studies have gone: Previous studies in osteosarcoma have shown variable outcomes; this study provides an additional historical reference rather than establishing a new standard of care.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathologically diagnosed high-grade osteosarcoma; age ≥12 years. * First-line treatment for high-grade osteosarcoma completed or ended at the study institution on or before 2021-06-30. * Core data required for survival endpoint assessment (EFS, PFS, OS) are available, with at least one of the following satisfied: (a) at least 12 months of follow-up from the date of diagnosis; or (b) an event (relapse, metastasis, disease progression, or death from any cause) confirmed within 12 months of diagnosis. Exclusion Criteria: * Primary tumor of soft-tissue origin rather than bone, confirmed pathologically. * History of a malignancy other than primary osteosarcoma, unless clinically insignificant and fully treated prior to osteosarcoma diagnosis with no investigator-judged impact on osteosarcoma treatment course or survival analysis. * Core data required for survival analysis cannot be verified. * Transferred to another institution with no available follow-up information, where neither event occurrence, last follow-up date, nor survival status can be determined from pre-transfer records. * Investigator-judged data errors or inconsistencies
Where it's running
-
National Cancer Center
Goyang-si, South Korea Recruiting -
Korea Cancer Center Hospital
Seoul, South Korea Recruiting -
Asan Medical Center
Seoul, South Korea Not yet recruiting -
Seoul National University Hospital
Seoul, South Korea Not yet recruiting
Study contacts
- Study coordinator: Sumin Kim
- Email: sumin.kim@medpacto.com
- Phone: +82 10 9743 0118
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.